We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+18.21%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.8B
AUM Growth
+$1.86B
Cap. Flow
-$1.4B
Cap. Flow %
-14.24%
Top 10 Hldgs %
73.27%
Holding
123
New
14
Increased
15
Reduced
12
Closed
2

Top Buys

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$247M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$188M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$112M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$91.9M
5
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$75.9M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$67.4M
2
XOMA
Xoma
XOMA
+$26.3M
3
AMBI
Ambit Biosciences Corp
AMBI
+$16.8M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$14.3M
5
RPRX
Repros Therapeutics Inc.
RPRX
+$6.64M

Sector Composition

Rank Sector Weight
1 Healthcare 42.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
26
Heron Therapeutics
HRTX
$95.4M
$26.2M 0.27%
2,607,784
– –
GILD icon
27
Gilead Sciences
GILD
$167B
$24.1M 0.25%
256,108
– –
CPRX
28
DELISTED
Catalyst Pharmaceutical
CPRX
$19.9M 0.2%
6,715,462
– –
RPRX
29
DELISTED
Repros Therapeutics Inc.
RPRX
$19.9M 0.2%
2,000,000
-778,654
-28% -$6.64M
AGIO icon
30
Agios Pharmaceuticals
AGIO
$2.12B
$18.3M 0.19%
163,393
-6,500
-4% -$580K
INSM icon
31
Insmed
INSM
$22.7B
$17.1M 0.17%
1,107,850
– –
OMER icon
32
Omeros
OMER
$851M
$16.1M 0.16%
648,101
-160,674
-20% -$2.93M
SGMO
33
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$14.5M 0.15%
955,332
+90,476
+10% +$1.1M
BLUE
34
DELISTED
bluebird bio
BLUE
$13.8M 0.14%
11,580
– –
NBIX icon
35
Neurocrine Biosciences
NBIX
$18.4B
$12.4M 0.13%
554,590
– –
CLVS
36
DELISTED
Clovis Oncology, Inc.
CLVS
$11.3M 0.12%
+202,630
New +$10.6M
MGNX icon
37
MacroGenics
MGNX
$239M
$10.9M 0.11%
311,891
– –
KYTH
38
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$9.93M 0.1%
286,255
-25,000
-8% -$872K
XNCR icon
39
Xencor
XNCR
$1.47B
$9.49M 0.1%
591,371
+49,008
+9% +$568K
ARWR icon
40
Arrowhead Research
ARWR
$12.3B
$9.08M 0.09%
1,230,802
– –
NGNE icon
41
Neurogene
NGNE
$675M
$9.08M 0.09%
60,518
-75
-0.1% -$10.7K
AERI
42
DELISTED
Aerie Pharmaceuticals
AERI
$8.74M 0.09%
299,356
– –
PRQR icon
43
ProQR Therapeutics
PRQR
$253M
$8.67M 0.09%
400,000
– –
OSIR
44
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$8.16M 0.08%
510,606
– –
VIRX
45
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$8.16M 0.08%
+15,238
New +$6.87M
LJPC
46
DELISTED
La Jolla Pharmaceutical Company
LJPC
$7.78M 0.08%
421,631
– –
ABUS icon
47
Arbutus Biopharma
ABUS
$861M
$7.33M 0.07%
484,156
– –
EIGR
48
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$7.32M 0.07%
833
– –
NVAX icon
49
Novavax
NVAX
$1.22B
$7.25M 0.07%
61,168
– –
ACGN
50
DELISTED
Aceragen Inc
ACGN
$7.18M 0.07%
11,984
+66
+0.6% +$26.5K
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2014 Portfolio in Review

As of Q4 2014, Baker Bros. Advisors held 123 positions worth $9.8B, up 23% from $7.94B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Baker Bros. Advisors withdrew a net $1.4B in Q4 2014, closing 2 positions and reducing 12 holdings. Its most notable exit was Ambit Biosciences Corp, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 39% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Bellicum Pharmaceuticals, Inc. worth $98.7M.

  • Baker Bros. Advisors's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 428,373 shares worth $98.7M.
  • Baker Bros. Advisors added most to AVANIR PHARMACEUTICALS, INC CL A in Q4 2014, an estimated $247M increase.
  • Baker Bros. Advisors's biggest Q4 2014 reduction was PHARMACYCLICS INC, cutting an estimated $67.4M.
  • Baker Bros. Advisors fully exited Ambit Biosciences Corp in Q4 2014, selling an estimated $16.8M.
  • Baker Bros. Advisors's ten largest holdings make up 73% of its $9.8B portfolio in Q4 2014.
  • Baker Bros. Advisors opened 14 new positions and closed 2 in Q4 2014.
  • Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $9.8B.

Based on Baker Bros. Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.